Latest On DURECT Corporation (DRRX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-08 23:08 EST | News | Durect GAAP EPS of -$0.52 beats by $0.01, revenue of $2.1M misses by $1.09M | N/A |  |
| 2023-05-08 23:07 EST | News | DURECT Corporation (DRRX) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-04-03 20:19 EST | News | Durect: Upcoming Catalyst, Strong Previous Data, Market Does Not Care | N/A | |
| 2023-03-21 19:13 EST | News | Gail Maderis appointed chair of DURECT | N/A | |
| 2023-03-08 09:00 EST | News | DURECT Corp (DRRX) Q4 2022 Earnings Call Transcript | N/A | |
About DURECT Corporation (DRRX):
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as read more...through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
General
- Name DURECT Corporation
- Symbol DRRX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 81
- Fiscal Year EndDecember
- IPO Date2000-09-28
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.durect.com
Valuation
- Price/Sales (Trailing 12 Mt.) 9.52
- Price/Book (Most Recent Quarter) 13.13
- Enterprise Value Revenue 14.39
- Enterprise Value EBITDA 401.35
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.19
- Next Year EPS Estimate -$0.26
- Next Quarter EPS Estimate -$0.05
- Profit Margin -2%
- Operating Margin -42%
- Return on Assets -10%
- Return on Equity -46%
- Revenue 30.11 million
- Earnings Per Share -$0.15
- Revenue Per Share $0.15
- Gross Profit 996000
- Quarterly Earnings Growth -79.3%
Highlights
- Market Capitalization 502.12 million
- EBITDA -22474000
- PE Ratio -2.91
- PEG Ratio -0.46
- Analyst Target Price $6.67
- Book Value Per Share $0.20
Share Statistics
- Shares Outstanding 224.49 million
- Shares Float 206.09 million
- % Held by Insiders 159%
- % Held by Institutions 55.03%
- Shares Short 8.81 million
- Shares Short Prior Month 6.89 million
- Short Ratio 2.16
- Short % of Float 4%
- Short % of Shares Outstanding 4%
Technicals
- Beta 1.53
- 52 Week High $2.96
- 52 Week Low $1.19
- 50 Day Moving Average 2.36
- 200 Day Moving Average 2.02
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
DURECT Corporation (DRRX) Dividend Calendar:
DURECT Corporation (DRRX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
DURECT Corporation (DRRX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
DURECT Corporation (DRRX) Chart:
DURECT Corporation (DRRX) News:
Below you will find a list of latest news for DURECT Corporation (DRRX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
DURECT Corporation (DRRX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest DRRX Trades:
DURECT Corporation (DRRX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-04 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-11-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-03 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-02 | 8-K (Current report) | |
| 2020-11-02 | 8-K (Current report) | |
| 2020-10-05 | 8-K (Current report) | |
| 2020-09-23 | 8-K (Current report) | |
| 2020-09-22 | 8-K (Current report) | |
| 2020-09-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-27 | 8-K (Current report) | |
| 2020-08-04 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-04 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-08-03 | 8-K (Current report) | |
| 2020-07-01 | 8-K (Current report) | |
| 2020-07-01 | 8-K (Current report) | |
| 2020-06-29 | 8-K (Current report) | |
| 2020-06-26 | 8-K (Current report) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-18 | 4 (Statement of changes in beneficial ownership of securities) | |
DURECT Corporation (DRRX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of DURECT Corporation (DRRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 159%
Institutional Ownership: 5503%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-01 | LP Bleichroeder | 10% Share Holder | Sell | 250,000.00 | 1.68 | 420,000.00 | 26,414,656.00 | |
| 2020-06-03 | Judy R Joice | Sr. VP Operations & Corp QA | Sell | 34,864.00 | 2.45 | 85,479.56 | 32,747.00 | |
| 2020-06-03 | Judy R Joice | Sr. VP Operations & Corp QA | Buy | 22,956.00 | 0.78 | 17,905.68 | 55,703.00 | |
| 2020-06-03 | Judy R Joice | Sr. VP Operations & Corp QA | Buy | 34,864.00 | 0.78 | 27,193.92 | 67,611.00 | |
| 2020-05-26 | LP Bleichroeder | 10% Share Holder | Sell | 39,388.00 | 2.50 | 98,525.14 | 26,664,656.00 | |
| 2020-02-06 | LP Bleichroeder | 10% Share Holder | Buy | 75,000.00 | 1.65 | 123,622.50 | 26,704,044.00 | |
| 2020-02-05 | LP Bleichroeder | 10% Share Holder | Buy | 74,998.00 | 1.69 | 126,776.62 | 26,629,044.00 | |
| 2020-02-04 | LP Bleichroeder | 10% Share Holder | Buy | 77,500.00 | 1.70 | 131,509.75 | 26,554,046.00 | |
| 2019-06-20 | First Eagle Investment Management, LLC | 10% Share Holder | Buy | 4,000,000.00 | 0.52 | 2,080,000.00 | 26,476,546.00 | |
| 2019-06-10 | JON S SAXE | Director | Buy | 287.00 | 0.54 | 155.78 | 125,287.00 | |
| 2019-06-10 | JON S SAXE | Director | Buy | 1,200.00 | 0.54 | 652.56 | 126,487.00 | |
| 2019-06-10 | JON S SAXE | Director | Buy | 200.00 | 0.54 | 108.78 | 126,687.00 | |
| 2019-06-10 | JON S SAXE | Director | Buy | 15.00 | 0.54 | 8.16 | 126,702.00 | |
| 2019-06-10 | JON S SAXE | Director | Buy | 300.00 | 0.54 | 163.29 | 127,002.00 | |
| 2019-06-10 | JON S SAXE | Director | Buy | 100.00 | 0.54 | 54.44 | 127,102.00 | |
| 2019-06-10 | JON S SAXE | Director | Buy | 7,898.00 | 0.54 | 4,303.62 | 135,000.00 | |
| 2019-06-10 | JON S SAXE | Director | Buy | 100.00 | 0.55 | 54.51 | 135,100.00 | |
| 2019-06-10 | JON S SAXE | Director | Buy | 1,751.00 | 0.55 | 955.00 | 136,851.00 | |
| 2019-06-10 | JON S SAXE | Director | Buy | 300.00 | 0.55 | 163.65 | 137,151.00 | |
| 2019-06-10 | JON S SAXE | Director | Buy | 1,400.00 | 0.55 | 764.26 | 138,551.00 | |